ProCE Banner Activity

Expert Guidance on Therapeutic Strategies for Multiple Myeloma

Text Module
Get multidisciplinary insights on the latest treatment strategies for multiple myeloma including advances across the disease spectrum, from smoldering myeloma to relapsed/refractory disease.

Released: May 01, 2020

Expiration: April 30, 2021

No longer available for credit.

Share

Faculty

Charise Gleason

Charise Gleason, MSN, NP-C, AOCNP

VP and Chief APP Officer
Emory Healthcare
NP Myeloma Program Winship Cancer Institute
Adjunct Faculty
Nell Hodgson Woodruff School of Nursing
Atlanta, Georgia

Sagar Lonial

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Kathryn Maples

Kathryn Maples, PharmD, BCOP

Clinical Pharmacy Specialist, Multiple Myeloma
Department of Pharmacy
Emory Healthcare
Winship Cancer Institute
Atlanta, Georgia

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

Celgene

Janssen administered by Scientific Affairs

Oncopeptides

Faculty Disclosure

Primary Author

Charise Gleason, MSN, NP-C, AOCNP

VP and Chief APP Officer
Emory Healthcare
NP Myeloma Program Winship Cancer Institute
Adjunct Faculty
Nell Hodgson Woodruff School of Nursing
Atlanta, Georgia

Charise Gleason, MSN, NP-BC, AOCNP, has disclosed that she has received consulting fees from Celgene, Karyopharm, and Takeda.

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Sagar Lonial, MD, has disclosed that he has received consulting fees from Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Karyopharm, Merck, and Novartis.

Kathryn Maples, PharmD, BCOP

Clinical Pharmacy Specialist, Multiple Myeloma
Department of Pharmacy
Emory Healthcare
Winship Cancer Institute
Atlanta, Georgia

Kathryn Maples, PharmD, BCOP, has no relevant conflicts of interest to report.

Staff Disclosure

Staff

Jason J. Everly, PharmD

Jason J. Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has reported that his spouse/partner has ownership interest (stock) in AstraZeneca.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy Quill, PhD, has no relevant conflicts of interest to report.

Kristen Rosenthal, PhD

Clinical Editor

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.